Sec Form 4 Filing - Papandrea Giuseppe @ ZYNEX INC - 2021-04-14

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person Papandrea Giuseppe 2. Issuer Name and Ticker or Trading Symbol ZYNEX INC [ ZYXI] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director _____ 10% Owner X __ Officer (give title below) _____ Other (specify below) COO - Zynex Medical, Inc. (Last) (First) (Middle) C/O ZYNEX, INC., 9555 MAROON CIRCLE 3. Date of Earliest Transaction (MM/DD/YY) 04/14/2021 (Street) ENGLEWOOD, CO80112 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 04/14/2021 M 24,093 A 30,828 D Common Stock 04/14/2021 M 666 A 31,494 D Common Stock 04/14/2021 F 438 D 31,056 D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expi ration Date Title Amount or Number of Shares Options to Purchase Common Stock ( 1 ) $ 7.87 04/14/2021 M 50,000 07/22/2020 07/22/2029 Common Stock 24,093 ( 2 ) 0 D Options to Purchase Common Stock ( 2 ) $ 8.96 04/14/2021 M 1,625 12/12/2020 12/12/2029 Common Stock 666 ( 3 ) 0 D

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other Papandrea Giuseppe C/O ZYNEX, INC. 9555 MAROON CIRCLE ENGLEWOOD, CO80112 COO - Zynex Medical, Inc. Signatures /s/ Giuseppe Papandrea 04/16/2021 Signature of Reporting Person Date

Explanation of Responses:

( 1 )Reflects the exercise of 50,000 vested options at an exercise price of $7.87 per share less the number of shares to fund the cashless exercise of such options at the market price of $15.19 per share. ( 2 )Reflects the exercise of 1,625 vested options at an exercise price of $8.96 per share less the number of shares to fund the cashless exercise of such options at the market price of $15.19 per share. ( 3 )Represents the number of shares of Common Stock that have been withheld by the issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of the shares underlying the exercised options. There was no sale involved in this cashless transaction.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.